Xencor (NASDAQ:XNCR) Stock Rating Lowered by StockNews.com

Xencor (NASDAQ:XNCR - Get Free Report) was downgraded by equities researchers at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Friday.

Other equities analysts have also issued reports about the stock. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $20.00 to $30.00 in a report on Monday, December 2nd. Wells Fargo & Company lowered their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Xencor currently has a consensus rating of "Moderate Buy" and a consensus target price of $34.38.

Xencor Stock Up 1.7 %

Shares of NASDAQ XNCR traded up $0.22 during midday trading on Friday, reaching $12.98. 582,093 shares of the company's stock traded hands, compared to its average volume of 560,031. The company has a market cap of $914.60 million, a price-to-earnings ratio of -4.06 and a beta of 0.74. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock's 50 day simple moving average is $17.36 and its 200-day simple moving average is $20.47. Xencor has a one year low of $12.69 and a one year high of $27.24.

Remove Ads

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million during the quarter, compared to analyst estimates of $17.14 million. On average, analysts predict that Xencor will post -3.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Xencor

Several institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. lifted its stake in shares of Xencor by 147.3% in the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company's stock worth $62,748,000 after buying an additional 1,858,440 shares during the last quarter. RTW Investments LP grew its holdings in shares of Xencor by 317.9% in the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock worth $55,218,000 after purchasing an additional 1,827,883 shares during the last quarter. BVF Inc. IL raised its position in Xencor by 169.3% in the 4th quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock valued at $52,596,000 after purchasing an additional 1,438,760 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of Xencor by 452.4% during the fourth quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company's stock worth $19,236,000 after purchasing an additional 685,557 shares in the last quarter. Finally, Finepoint Capital LP bought a new stake in shares of Xencor during the fourth quarter worth approximately $15,167,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.